Kovitz Investment Group Partners LLC Purchases New Shares in Galectin Therapeutics Inc. (NASDAQ:GALT)

Kovitz Investment Group Partners LLC acquired a new stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) during the 3rd quarter, HoldingsChannel reports. The firm acquired 42,540 shares of the company’s stock, valued at approximately $117,000.

A number of other hedge funds have also recently bought and sold shares of GALT. State Street Corp grew its holdings in shares of Galectin Therapeutics by 9.3% in the third quarter. State Street Corp now owns 251,014 shares of the company’s stock valued at $690,000 after acquiring an additional 21,399 shares in the last quarter. Gladstone Institutional Advisory LLC purchased a new position in Galectin Therapeutics in the third quarter worth $60,000. Retirement Guys Formula LLC grew its stake in Galectin Therapeutics by 55.1% in the 3rd quarter. Retirement Guys Formula LLC now owns 63,817 shares of the company’s stock valued at $175,000 after purchasing an additional 22,660 shares during the period. Sanctuary Advisors LLC purchased a new stake in shares of Galectin Therapeutics during the 2nd quarter valued at $227,000. Finally, Squarepoint Ops LLC raised its stake in shares of Galectin Therapeutics by 75.4% during the 2nd quarter. Squarepoint Ops LLC now owns 84,074 shares of the company’s stock worth $190,000 after purchasing an additional 36,139 shares during the period. 11.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GALT. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Galectin Therapeutics in a research report on Friday, November 15th. StockNews.com upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th.

Galectin Therapeutics Price Performance

NASDAQ:GALT opened at $2.11 on Friday. The company has a market capitalization of $132.42 million, a P/E ratio of -2.89 and a beta of 0.69. The business has a fifty day simple moving average of $2.59 and a two-hundred day simple moving average of $2.52. Galectin Therapeutics Inc. has a 1 year low of $1.56 and a 1 year high of $4.27.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.